Detection of cancer DNA in plasma of patients with early-stage breast cancer

Clinical Cancer Research

Volumn 20, Issue 10, 2014, Pages 2643-2650

  Beaver, Julia A ^a   Jelovac, Danijela ^a   Balukrishna, Sasidharan ^f   Cochran, Rory L ^a   Croessmann, Sarah ^a   Zabransky, Daniel J ^a   Wong, Hong Yuen ^a   Toro, Patricia Valda ^a   Cidado, Justin ^a   Blair, Brian G ^a   Chu, David ^a   Burns, Timothy ^b   Higgins, Michaela J ^c   Stearns, Vered ^a   Jacobs, Lisa ^a   Habibi, Mehran ^a   Lange, Julie ^a   Hurley, Paula J ^a   Lauring, Josh ^a   VanDenBerg, Dustin A ^a   Kessler, Jill ^a   Jeter, Stacie ^a   Samuels, Michael L ^d   Maar, Dianna ^e   Cope, Leslie ^a   Cimino Mathews, Ashley ^a   Argani, Pedram ^a   Wolff, Antonio C ^a   Park, Ben Ho ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d RainDance Technologies   (United States)

^e BIO RAD LABORATORIES   (United States)

^f CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PLASMA TUMOR DNA; TUMOR MARKER; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL POLYMERASE CHAIN REACTION; EARLY CANCER; EXON; GENE MUTATION; H1047R GENE; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; ONCOGENE; PARTIAL MASTECTOMY; PIK3CA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; BLOOD; BREAST NEOPLASMS; CANCER STAGING; CHEMISTRY; FEMALE; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROCEDURES; REPRODUCIBILITY;

ADULT; AGED; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84900992934     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2933     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
2. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
3. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006;3:551-9.
4. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14: 985-90.
5. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012;18:3462-9.
6. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010;2:20ra14.
7. Leary RJ, Sausen M, Kinde I, PapadopoulosN,Carpten JD,CraigD, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012;4:162ra54.
8. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
9. Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic acids 2013;2:e109.
10. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 2013;10:1003-5.
11. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 2000;906:161-8.
12. Choi JJ, Reich CF 3rd, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 2005;115:55-62.
13. Lippman M, Osborne CK. Circulating tumor DNA-ready for prime time? N Engl J Med 2013;368:1249-50.
14. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005;102:16368-73.
15. Baker M. Digital PCR hits its stride. Nat Methods 2012;9:541-4.
16. Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat 2010;120:461-7.
17. Castells A, Puig P, Mora J, Boadas J, Boix L, Urgell E, et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 1999;17:578-84.
18. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring Kras mutations with the use of plasma DNA. J Natl Cancer Inst 2000;92:918-23.
19. Dianxu F, Shengdao Z, Tianquan H, Yu J, Ruoqing L, Zurong Y, et al. A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas 2002;25:336-41.
20. Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 2013;17:205-16.
21. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94:455-9.
22. Distribution of Somatic Mutations in PIK3CA.Catalogue of Somatic Mutations in Cancer (COSMIC) 2011. Available from: http://www. sanger.ac.uk/genetics/CGP/cosmic/. Accessed April 21, 2013.
23. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-5.
24. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
25. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-9.
26. Allen D, Butt A, Cahill D, Wheeler M, Popert R, Swaminathan R. Role of cell-free plasmaDNAas a diagnostic marker for prostate cancer. AnnN Y Acad Sci 2004;1022:76-80.
27. Chun FK, Muller I, Lange I, Friedrich MG, Erbersdobler A, Karakiewicz PI, et al. Circulating tumour-Associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 2006;98:544-8.
28. Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci 2008;1137:190-6.
29. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-A survey. Biochim Biophys Acta 2007;1775:181-232.
30. Lee H, Jung SY, Ro JY, Kwon Y, Sohn JH, Park IH, et al. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol 2012;65:441-6.
31. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptorpositive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381:805-16.
32. Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M. Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer 2008;8:411-7.
33. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68:6084-91.